CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

Original Research2021 Jan 12;S0828-282X(21)00005-2.

JOURNAL:Can J Cardiol. Article Link

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease

E O'Meara, S Verma. Keywords: SGLT2 inhibitors; heart failure; chronic kidney disease

Full Text PDF